[Skip to Content]
[Skip to Content Landing]
December 1995

Budesonide Patch Testing

Author Affiliations

Department of Dermatology Ochsner Clinic and Alton Ochsner Medical Foundation 1516 Jefferson Hwy New Orleans, LA 70121

Arch Dermatol. 1995;131(12):1466-1467. doi:10.1001/archderm.1995.01690240132032

When I editorialized on patch testing for corticosteroid allergy, budesonide was unavailable in the United States.1 Late in 1994, the US Food and Drug Administration approved a new nasal inhaler known as Rhinocort, which is budesonide made available in a metered-dose apparatus. The 7-g canister contains 200 metered doses, each containing approximately 32 mg of micronized budesonide.

I had the opportunity to conduct a patch test on a patient with 0.1% budesonide in petrolatum, and an extreme reaction (3+) developed at 96 hours. I recently retested him with budesonide sprayed directly into a Finn chamber and applied to his back. This was done with one activation directly to the Finn chamber, with successive Finn chambers containing additional activations, up to a total of nine activations. He underwent retesting with 0.1% budesonide in petrolatum. At 48 hours, all of the tests showed equally positive results, indicating that one activation

First Page Preview View Large
First page PDF preview
First page PDF preview